European equities traded in the US as American depositary receipts kicked off the week higher late Monday morning, rising 1.12% to 1,433.84 on the S&P Europe Select ADR Index. From continental Europe, ...

In a report released today, Vikram Purohit from Morgan Stanley maintained a Buy rating on Legend Biotech (LEGN – Research Report), with a price ...

Morgan Stanley analyst Vikram Purohit maintained a Hold rating on Ascendis Pharma (ASND – Research Report) today and set a price target of ...

A phase 3 trial of AstraZeneca’s $800 million rare disease candidate has met its primary endpoint. The update keeps ...

Assetmark Inc. raised its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND – Free Report) by 32.9% in the 4th quarter, ...

Ascendis Health's journey from near-bankruptcy to profitability showcases how strategic leadership and financial discipline ...

Buying $1000 In ASND: If an investor had bought $1000 of ASND stock 15 years ago, it would be worth $55,812.96 today based on a price of $151.93 for ASND at the time of writing.

Over the last 7 days, the United States market has experienced a slight decline of 1.3%, yet it has shown resilience with a 15% increase over the past year and earnings forecast to grow by 14% ...

Shares of Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) have received an average rating of “Moderate Buy” from the fourteen brokerages that are covering the stock, MarketBeat reports.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

COPENHAGEN, Denmark, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a fireside chat at the TD Cowen 45th Annual ...